Cancer treatment involves a constant battle with oxygen. Tumors thrive in low-oxygen environments, and radiation therapy works best when oxygen is present. This relationship has led researchers to investigate whether delivering extra oxygen through hyperbaric oxygen therapy (HBOT) could improve cancer treatment outcomes. The research spans decades, and the answer is more nuanced than you might expect.
This article covers how oxygen therapy works alongside cancer treatment, what the Cochrane review found, which cancer types have the most evidence, and why the old myth that “oxygen feeds cancer” is scientifically backwards.
Key Takeaways
- HBOT can act as a radiosensitizer, making radiation therapy more effective against certain tumors
- The 2005 Cochrane review (Mayer et al.) found HBOT improved local tumor control and mortality in head and neck cancers when combined with radiation
- Evidence varies significantly by cancer type; head/neck cancers have the strongest data
- The idea that oxygen “feeds” cancer is a myth; tumor hypoxia actually promotes cancer progression and treatment resistance
- HBOT is FDA-approved for radiation injury treatment and is used in several cancer-related contexts
Oxygen and Cancer: The Biological Relationship
To understand why oxygen therapy matters in cancer care, you need to understand tumor hypoxia.
As tumors grow, they outpace their blood supply. The center of a solid tumor often receives far less oxygen than normal tissue. This low-oxygen environment, known as hypoxia, is not just a byproduct of growth. It actively drives cancer progression by:
- Activating hypoxia-inducible factor (HIF-1), which promotes angiogenesis and metastasis
- Making cancer cells resistant to radiation therapy (oxygen is needed for radiation to generate DNA-damaging free radicals)
- Reducing the effectiveness of certain chemotherapy drugs
- Promoting a more aggressive, treatment-resistant tumor phenotype
This is why the notion that oxygen “feeds” cancer is not just wrong; it is the opposite of what the science shows. Hypoxia feeds cancer aggressiveness. Oxygen can be an ally in treatment.
How HBOT Works as a Radiosensitizer
Radiation therapy kills cancer cells primarily by generating free radicals that damage DNA. This process is heavily oxygen-dependent. When oxygen is present, the free radicals form stable, irreparable DNA lesions. When oxygen is absent, the damage can be repaired by the cell.
This is called the “oxygen enhancement ratio” (OER), and it has been documented since the 1950s. Tumors with well-oxygenated cells are roughly 2.5 to 3 times more sensitive to radiation than hypoxic cells (Hall & Giaccia, 2012).
HBOT delivers 100% medical-grade oxygen at pressures typically between 2.0 and 2.5 ATA (atmospheres absolute). This increases dissolved oxygen in the blood plasma by 10 to 15 times normal levels. The goal when used alongside radiation is to temporarily overcome tumor hypoxia, creating a window during which radiation is maximally effective.
The oxygen enhancement ratio has been documented for over 60 years. Radiation is 2.5 to 3 times more effective against well-oxygenated tumors than hypoxic ones. HBOT exploits this biology directly.
The Cochrane Review: Mayer et al. (2005)
The most comprehensive analysis of HBOT in cancer treatment is the Cochrane systematic review by Mayer and colleagues, published in 2005. This review examined 19 randomized controlled trials involving 2,286 patients.
The key findings:
| Outcome | Finding | Statistical Significance |
|---|---|---|
| Local tumor control (head/neck) | Significant improvement with HBOT + radiation vs. radiation alone | RR 1.19 (95% CI: 1.07-1.33) |
| Mortality (head/neck) | Significant reduction in mortality | RR 0.83 (95% CI: 0.70-0.98) |
| Local recurrence (head/neck) | Significant reduction | RR 0.58 (95% CI: 0.39-0.85) |
| Bladder cancer | Some improvement in local control, but smaller effect | Borderline significance |
| Cervical cancer | Mixed results across trials | Not consistently significant |
The review also noted an increased risk of severe radiation tissue injury (oxygen toxicity seizures occurred in about 2% of HBOT patients), but overall concluded that HBOT combined with radiation showed therapeutic benefit for head and neck cancers (Mayer et al., 2005).
It is worth noting that many of the included trials were conducted in the 1960s through 1980s, and modern radiation techniques (IMRT, proton therapy) have changed the treatment landscape considerably. Updated trials with current protocols are needed.
Evidence by Cancer Type
| Cancer Type | Evidence Level | Key Findings |
|---|---|---|
| Head and neck | Moderate (RCTs available) | Improved tumor control and survival when HBOT combined with radiation |
| Cervical | Low to moderate | Mixed results; some trials showed benefit with radiation |
| Bladder | Low to moderate | Some evidence of improved local control |
| Breast | Low (mostly preclinical) | Animal studies show reduced hypoxia; limited human data |
| Glioblastoma | Emerging | Small trials combining HBOT with radiation; results promising but preliminary |
| Radiation injury (all types) | Strong (FDA-approved) | HBOT is standard of care for radiation cystitis, proctitis, and osteoradionecrosis |
For a deeper look at HBOT specifically in cancer treatment, see our comprehensive guide on HBOT for cancer treatment.
Debunking the Myth: Does Oxygen Feed Cancer?
This misconception persists partly because of a misunderstanding of the Warburg effect. In the 1920s, Otto Warburg observed that cancer cells preferentially use glycolysis (sugar fermentation) for energy even when oxygen is available. Some people interpreted this to mean cancer cells thrive on oxygen deprivation and that giving more oxygen would fuel growth.
The science shows the opposite:
- Tumor hypoxia promotes aggressiveness. Low oxygen triggers HIF-1 activation, which promotes angiogenesis, metastasis, and treatment resistance (Semenza, 2012).
- HBOT does not promote tumor growth. A systematic review by Moen and Stuhr (2012) examined 32 studies and found no evidence that HBOT stimulated cancer growth. In fact, some studies showed tumor-inhibiting effects.
- The Warburg effect is about metabolic preference, not oxygen dependency. Cancer cells use glycolysis because it produces metabolic intermediates needed for rapid cell division, not because oxygen is harmful to them.
This is an important point for patients who may have been told to avoid oxygen therapy because of cancer. The evidence does not support that concern.
Current Clinical Trials
Several clinical trials are investigating oxygen-based interventions in cancer:
- HBOT combined with immunotherapy for various solid tumors (investigating whether reducing tumor hypoxia enhances immune checkpoint inhibitor effectiveness)
- HBOT as a radiosensitizer for glioblastoma multiforme
- Normobaric oxygen as a lower-cost alternative to HBOT in radiation sensitization
- HBOT for prevention and treatment of radiation-induced complications
Patients interested in clinical trials can search ClinicalTrials.gov for “hyperbaric oxygen” and “cancer” for the most current listings.
HBOT vs. Supplemental Oxygen
Standard supplemental oxygen (delivered via nasal cannula or mask at normal atmospheric pressure) increases blood oxygen saturation but does not significantly increase dissolved oxygen in plasma. Only HBOT, which uses pressure to dissolve oxygen directly into the blood plasma, can achieve the supraphysiological oxygen levels needed to overcome tumor hypoxia.
This distinction matters because some patients assume that home oxygen concentrators or oxygen bars can provide similar benefits. They cannot. The pressurized environment of an HBOT chamber is what drives the therapeutic oxygen levels into tissue.
The Bottom Line
Oxygen therapy, specifically HBOT, has a legitimate scientific basis in cancer care. The radiosensitization mechanism is well-established in physics and biology, and clinical data (particularly from the Mayer Cochrane review) shows measurable benefits in head and neck cancers when combined with radiation.
However, HBOT is not a standalone cancer treatment. Its role is adjunctive, and its benefits appear to be cancer-type specific. The myth that oxygen feeds cancer is not supported by evidence; on the contrary, tumor hypoxia drives progression and treatment resistance.
For cancer patients considering HBOT, the most evidence-supported use cases are radiation sensitization (particularly for head/neck cancers) and treatment of radiation injury, where HBOT is already FDA-approved and part of standard care.
References
- Hall, E. J., & Giaccia, A. J. (2012). Radiobiology for the Radiologist (7th ed.). Lippincott Williams & Wilkins.
- Mayer, R., Hamilton-Farrell, M. R., van der Kleij, A. J., et al. (2005). Hyperbaric oxygen and radiotherapy. Strahlentherapie und Onkologie, 181(2), 113-123. doi:10.1007/s00066-005-1277-y
- Moen, I., & Stuhr, L. E. B. (2012). Hyperbaric oxygen therapy and cancer: A review. Targeted Oncology, 7(4), 233-242. doi:10.1007/s11523-012-0233-x
- Semenza, G. L. (2012). Hypoxia-inducible factors in physiology and medicine. Cell, 148(3), 399-408. doi:10.1016/j.cell.2012.01.021
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
